Getting TRAIL back on track for cancer therapy

JV Lemke, S von Karstedt, J Zinngrebe… - Cell Death & …, 2014 - nature.com
Unlike other members of the TNF superfamily, the TNF-related apoptosis-inducing ligand
(TRAIL, also known as Apo2L) possesses the unique capacity to induce apoptosis …

Developing TRAIL/TRAIL death receptor-based cancer therapies

X Yuan, A Gajan, Q Chu, H Xiong, K Wu… - Cancer and Metastasis …, 2018 - Springer
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the
TNF superfamily that can initiate the apoptosis pathway by binding to its associated death …

Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects

JE Allen, G Krigsfeld, PA Mayes, L Patel… - Science translational …, 2013 - science.org
Recombinant tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is an
antitumor protein that is in clinical trials as a potential anticancer therapy but suffers from …

The TRAIL to cancer therapy: Hindrances and potential solutions

SHM Wong, WY Kong, CM Fang, HS Loh… - Critical reviews in …, 2019 - Elsevier
Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and
pathological conditions. Resistance to apoptosis is a hallmark of virtually all malignancies …

On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics

LY Dimberg, CK Anderson, R Camidge, K Behbakht… - Oncogene, 2013 - nature.com
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and agonistic antibodies
against TRAIL death receptors (DR) kill tumor cells while causing virtually no damage to …

Genome-wide meta-analyses of breast, ovarian, and prostate cancer association studies identify multiple new susceptibility loci shared by at least two cancer types

SP Kar, J Beesley, A Amin Al Olama, K Michailidou… - Cancer discovery, 2016 - AACR
Breast, ovarian, and prostate cancers are hormone-related and may have a shared genetic
basis, but this has not been investigated systematically by genome-wide association (GWA) …

Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non–small-cell lung cancer

JC Soria, Z Márk, P Zatloukal, B Szima… - Journal of Clinical …, 2011 - ascopubs.org
Purpose To evaluate the efficacy and safety of dulanermin combined with paclitaxel and
carboplatin (PC) and bevacizumab (PCB) as first-line treatment for advanced or recurrent …

Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy

X Dai, J Zhang, F Arfuso… - Experimental …, 2015 - journals.sagepub.com
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to
selectively induce apoptotic cell death in various tumor cells by engaging its death-inducing …

Death receptors as targets in cancer

O Micheau, S Shirley, F Dufour - British journal of …, 2013 - Wiley Online Library
Anti‐tumour therapies based on the use pro‐apoptotic receptor agonists, including TNF‐
related apoptosis‐inducing ligand (TRAIL) or monoclonal antibodies targeting TRAIL‐R1 or …

Cancer therapeutics: Targeting the apoptotic pathway

KH Khan, M Blanco-Codesido, LR Molife - Critical reviews in oncology …, 2014 - Elsevier
Apoptosis, a physiological process of programmed cell death, is disrupted in various
malignancies. It has been exploited as an anti-cancer strategy traditionally by inducing DNA …